RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Image by Peggy und Marco Lachmann-Anke from Pixabay
by Jim Shamp, NCBiotech Writer May 27, 2021 .
RESEARCH TRIANGLE PARK – Research Triangle Park regenerative wound-healing product developer Merakris Therapeutics is launching human testing of a liquid to treat open sores on the skin known as non-healing venous stasis ulcers (VSUs).
Merakris has received U.S. Food and Drug Administration clearance for a Phase 2 clinical trial to test its investigational therapy, Dermacyte Amniotic Wound Care Liquid. The study will address the drug’s frequency of administration, safety and efficacy.
Merakris
CEO Chris Broderick said the team at Merakris – which includes experts in regulatory affairs, good clinical practices, clinical data management, and clinical trial design and oversight – will manage the study. It will work with a Good Manufacturing Practices laboratory partner to ensure that the investigational product is manufactured in accordance with all FDA requirements.